The eye-drug pricing war just got tighter for Roche’s injection Lucentis: An NIH-funded study comparing Lucentis (ranibizumab) against its cancer drug Avastin (bevacizumab) as well as Regeneron’s ...

But Eylea may have an edge over Lucentis as it is slightly cheaper at $1,850 per injection, compared to $1,950 for Roche and Novartis’ drug. As it also requires fewer injections – once a month for the ...

Based on Medicare allowable charges, the per-injection costs of each drug at the doses used in this study were about $1850 for Eylea, about $60 for Avastin, and about $1200 for Lucentis.

A closely watched, two-year goverment-funded study found that Lucentis and Avastin are roughly equivalent in treating wet AMD, a leading cause of blindness in the elderly. The results, however ...

Eylea (aflibercept), as compared to Avastin (bevacizumab) or Lucentis (ranibizumab) provided greater visual improvement for diabetic macular edema (DME), when vision was 20/50 or worse.

"The study suggests there is little advantage of choosing Eylea or Lucentis over Avastin when a patient's loss of visual acuity from macular edema is mild, meaning a visual acuity of 20/40 or better.

Eylea is Regeneron's flagship drug and the news of the positive results from the National Institutes of Health sponsored study drove shares up 6 percent to $362.50 in early pre-market trading.

Since outcomes from the recent study were the same for patients with mild vision loss, patients should receive Roche's Avastin, which rings in at $50 a vial--cheaper still than Eylea and Lucentis ...

Both results missed analyst expectations and suggest Eylea is perhaps benefitting from a recent study showing superiority to Lucentis and Roche’s Avastin (bevacizumab) – used off-label – in a ...

Bayer and Regeneron’s eye drug Eylea has matched its rival Lucentis in a new head-to-head trial. Bayer and Regeneron’s eye drug Eylea has matched its rival Lucentis in a new head-to-head trial. Eylea ...

Oct 17 (Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in ...